302 related articles for article (PubMed ID: 28533670)
1. Diagnostic value of gadobenate dimeglumine-enhanced hepatocyte-phase magnetic resonance imaging in evaluating hepatic fibrosis and hepatitis.
Li XM; Chen Z; Xiao EH; Shang QL; Ma C
World J Gastroenterol; 2017 May; 23(17):3133-3141. PubMed ID: 28533670
[TBL] [Abstract][Full Text] [Related]
2. The relationship between liver function and liver parenchymal contrast enhancement on Gd-BOPTA-enhanced MR imaging in the hepatocyte phase.
Zhao X; Huang M; Zhu Q; Wang T; Liu Q
Magn Reson Imaging; 2015 Jul; 33(6):768-73. PubMed ID: 25842259
[TBL] [Abstract][Full Text] [Related]
3. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
[TBL] [Abstract][Full Text] [Related]
4. Effect of increasing the flip angle during the hepatocyte phase of gadobenate dimeglumine-enhanced 1.5T MRI in cirrhotic patients with hepatocellular carcinoma.
Lee EJ; Kim DJ; Cho ES; Kim KA
J Magn Reson Imaging; 2016 Mar; 43(3):713-9. PubMed ID: 26290384
[TBL] [Abstract][Full Text] [Related]
5. Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose.
Nural MS; Gokce E; Danaci M; Bayrak IK; Diren HB
Eur J Radiol; 2008 Apr; 66(1):65-74. PubMed ID: 17555901
[TBL] [Abstract][Full Text] [Related]
6. [Diagnostic value of gadobenate dimeglumine enhanced MRI in hepatic fibrosis of rats].
Yu R; Ni XQ; Ya Y; Fan GH
Zhonghua Yi Xue Za Zhi; 2019 Nov; 99(43):3428-3431. PubMed ID: 31752473
[No Abstract] [Full Text] [Related]
7. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison.
Schneider G; Maas R; Schultze Kool L; Rummeny E; Gehl HB; Lodemann KP; Kirchin MA
Invest Radiol; 2003 Feb; 38(2):85-94. PubMed ID: 12544071
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC
J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
[TBL] [Abstract][Full Text] [Related]
9. Comparison of gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for enhanced MR imaging of brain and spine tumours in children.
Colosimo C; Demaerel P; Tortori-Donati P; Christophe C; Van Buchem M; Högström B; Pirovano G; Shen N; Kirchin MA; Spinazzi A
Pediatr Radiol; 2005 May; 35(5):501-10. PubMed ID: 15678342
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the hepatocyte-specific contrast agent gadobenate dimeglumine for MR imaging of acute hepatitis in a rat model.
Marzola P; Maggioni F; Vicinanza E; Daprà M; Cavagna FM
J Magn Reson Imaging; 1997; 7(1):147-52. PubMed ID: 9039606
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Gadolinium-BOPTA and Ferucarbotran-enhanced three-dimensional T1-weighted dynamic liver magnetic resonance imaging in the same patient.
Wersebe A; Wiskirchen J; Decker U; Schick F; Dietz K; Müller-Schimpfle M; Claussen CD; Pereira PL
Invest Radiol; 2006 Mar; 41(3):264-71. PubMed ID: 16481909
[TBL] [Abstract][Full Text] [Related]
12. Ascites relative enhancement during hepatobiliary phase after Gd-BOPTA administration: a new promising tool for characterising abdominal free fluid of unknown origin.
Bonatti M; Valletta R; Zamboni GA; Lombardo F; Senoner M; Simioni M; Schifferle G; Bonatti G
Eur Radiol; 2019 Jun; 29(6):2830-2836. PubMed ID: 30643946
[TBL] [Abstract][Full Text] [Related]
13. Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine.
Bauner KU; Reiser MF; Huber AM
Invest Radiol; 2009 Feb; 44(2):95-104. PubMed ID: 19077911
[TBL] [Abstract][Full Text] [Related]
14. Gadobenate dimeglumine-enhanced magnetic resonance imaging can accurately predict the severity of esophageal varices and portal vein pressure in patients with hepatitis B cirrhosis.
Feng Q; Guan S; Zhao JR; Zhao XY; Zhang CC; Wang L; Feng YM; Li SL; Zhu Q
J Dig Dis; 2020 Feb; 21(2):104-111. PubMed ID: 31922658
[TBL] [Abstract][Full Text] [Related]
15. Detectability of small liver metastases with gadolinium BOPTA.
Runge VM; Lee C; Williams NM
Invest Radiol; 1997 Sep; 32(9):557-65. PubMed ID: 9291044
[TBL] [Abstract][Full Text] [Related]
16. Gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase can predict progression in patients with liver cirrhosis.
Liu C; Sun Y; Yang Y; Feng Y; Xie X; Qi L; Liu K; Wang X; Zhu Q; Zhao X
Eur Radiol; 2021 Aug; 31(8):5840-5850. PubMed ID: 33533990
[TBL] [Abstract][Full Text] [Related]
17. Focal fat deposition at liver MRI with gadobenate dimeglumine and gadoxetic acid: Quantitative and qualitative analysis.
Yeom SK; Byun JH; Kim HJ; Park SH; Kim N; Shin YM; Kim PN
Magn Reson Imaging; 2013 Jul; 31(6):911-7. PubMed ID: 23598063
[TBL] [Abstract][Full Text] [Related]
18. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers.
Brismar TB; Dahlstrom N; Edsborg N; Persson A; Smedby O; Albiin N
Acta Radiol; 2009 Sep; 50(7):709-15. PubMed ID: 19701821
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings.
Grazioli L; Morana G; Caudana R; Benetti A; Portolani N; Talamini G; Colombari R; Pirovano G; Kirchin MA; Spinazzi A
Invest Radiol; 2000 Jan; 35(1):25-34. PubMed ID: 10639033
[TBL] [Abstract][Full Text] [Related]
20. Hepatic abscesses. Magnetic resonance imaging findings using gadolinium-BOPTA.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1996 Dec; 31(12):781-8. PubMed ID: 8970881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
